BDBoya Deng

Boya Deng

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Boya Deng has a total of 13 co-authors. Here are the top co-authors by number of shared publications:

  • Lili Ren

    Department of Medicine, The University of Chicago, Chicago, IL 60637, USA

    2 shared publications
  • Jae-Hyun Park

    Department of Medicine, The University of Chicago, Chicago, IL 60637, USA

    1 shared publication
  • Jae‐Hyun Park

    Department of Medicine The University of Chicago Chicago IL USA

    1 shared publication
  • Kazuma Kiyotani

    Cancer Precision Medicine Research Center Japanese Foundation of Cancer Institute Tokyo Japan

    1 shared publication
  • Kelly O'COnnor

    Department of Medicine The University of Chicago Chicago IL USA

    1 shared publication
  • Koji Ueda

    Cancer Proteomics Group, Cancer Precision Medicine Research Center, Japanese Foundation for Cancer Research, Tokyo, 135-8550, Japan

    1 shared publication

Latest Publications

  • Open Access

    Critical Role of Estrogen Receptor Alpha O-Glycosylation by N-Acetylgalactosaminyltransferase 6 (GALNT6) in Its Nuclear Localization in Breast Cancer Cells

    by Boya Deng, Yunus Emre Tarhan, Koji Ueda, Lili Ren, Toyomasa Katagiri, Jae-Hyun Park, Yusuke Nakamura


  • Open Access

    CD8 lymphocytes in tumors and nonsynonymous mutational load correlate with prognosis of bladder cancer patients treated with immune checkpoint inhibitors

    by Boya Deng, Jae‐Hyun Park, Lili Ren, Poh Yin Yew, Kazuma Kiyotani, Tatjana Antic, Kelly O'COnnor, Peter H. O'DOnnell, Yusuke Nakamura

    Background: Anti–programed cell death 1 checkpoint inhibitors have recently demonstrated effectiveness against metastatic cancers including urothelial carcinoma.Aims: To identify biomarkers/factors that correlate with the clinical response in advanced bladder cancer patients who received immune checkpoint inhibitor treatment.Methods and results: We investigated tumors from 18 bladder cancer patients who had received anti–programed cell death 1 (pembrolizumab) or anti–programmed death‐ligand 1 therapy (atezolizumab or durvalumab) and performed exome analysis, T‐cell receptor sequencing of the tumor‐infiltrating lymphocytes (TILs), and immunohistochemical analysis of CD8 and programmed death‐ligand 1 in cancer tissues. Immunohistochemical analysis of bladder cancer tissues demonstrated that a higher number of CD8 T‐cell infiltration into cancer tissues was significantly associated with longer cancer‐specific survival of the patients (P = .0012). T‐cell receptor beta sequencing of TILs using genomic DNAs extracted from the tissues of 15 cases revealed that patients with higher clonal expansion of TILs had some tendency of longer cancer‐specific survival (P = .055), than those with lower clonal expansion. We performed whole exome sequencing of 14 cases and found that patients carrying higher numbers of somatic mutations received greater benefit from immunotherapy (P = .034) and one patient who had high microsatellite instability has survived for 1034 days.Conclusion: CD8 infiltration in tumors and nonsynonymous mutation load might be useful predictive markers for immune checkpoint inhibitors for bladder cancer patients.